Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease

Martin R. Farlow, Jeffrey L. Cummings, Jason T. Olin, Meng Xiangyi Meng

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Rivastigmine has beneficial effects on cognitive functioning in Alzheimer's disease (AD). Effects of cholinesterase inhibitors, particularly rivastigmine, on AD Assessment Scaleg-cognitive subscale (ADAS-cog) domains and individual items have rarely been analyzed. Results from 4 randomized, double-blind, placebo-controlled, 26-week rivastigmine capsule trials in patients with mild-to-moderate AD were pooled and ADAS-cog domains and individual items were evaluated. Data were available from 878, 1053, and 863 patients in the 1 to 4 mg/d, 6 to 12 mg/d, and placebo groups, respectively. Rivastigmine-treated groups were superior to placebo on total ADAS-cog and memory domain scores (P ≥ .0001). Rivastigmine 6 to 12 mg/d was also significantly better versus placebo on language (P <.001) and praxis (P <.001); greatest treatment responses were seen on memory items (P <.0001). Although rivastigmine was associated with dose-dependent improvements in all cognitive domains, largest effects were on memory items. Evaluation of ADAS-cog domain scores provides insight into test items most likely to respond to treatment.

Original languageEnglish (US)
Pages (from-to)347-352
Number of pages6
JournalAmerican Journal of Alzheimer's Disease and Other Dementias
Volume25
Issue number4
DOIs
StatePublished - Jun 2010

    Fingerprint

Keywords

  • Alzheimer's disease
  • Cognition
  • Language
  • Memory
  • Praxis
  • Rivastigmine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology
  • Medicine(all)

Cite this